 |
160 Products |  |
813 Diseases | | 160 Products |
|
1588 Trials |  |
77929 News |  |
| «12...892893894895896897898899900901902903904» |
- ||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Oncaspar liquid (pegaspargase) / Servier, lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Clinical: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 2, 2012
P3, N=315, Recruiting, Sponsor: Children's Oncology Group
N=244 --> 315
- buparlisib (AN2025) / Adlai Nortye, Vectibix (panitumumab) / Amgen
New P1/2 trial: P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer. (clinicaltrials.gov) - May 2, 2012
P1/2, N=40, Recruiting, Sponsor: NCIC Clinical Trials Group
- Vectibix (panitumumab) / Amgen
New P2 trial: Investigation of efficacy and safety of panitumumab in combination with irinotecan/5-fluorouracil/leucovorin (FOLFIRI) in patients with colorectal cancer liver metastasis (EUDRACT) - May 1, 2012
P2, N=36, Ongoing, Sponsor: ABCSG (Austrian Breast & Colorectal Cancer Study Group)
- |||||||||| Repatha (evolocumab) / Amgen, Astellas
New P2/3 trial: Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities (clinicaltrials.gov) - Apr 29, 2012
P2/3, N=58, Completed, Sponsor: Amgen
- ||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
New P1 trial: Transition From Alendronate to Romosozumab (AMG 785) (clinicaltrials.gov) - Apr 29, 2012
P1, N=60, Completed, Sponsor: Amgen
- |||| Ravicti (glycerol phenylbutyrate) / Immedica, Amgen
Trial completion: HALT-HE: A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy (clinicaltrials.gov) - Apr 29, 2012
P2, N=193, Completed, Sponsor: Hyperion Therapeutics, Inc.
N=244 --> 315 Active, not recruiting --> Completed
- Vectibix (panitumumab) / Amgen
New P2 trial: Phase II study of first-line WHIT panitumumab and capecitabine in elderly patients with metastatic colorectal cancer and wild type KRAS Estudio de fase II de panitumumab y capecitabina como tratamiento de primera l (EUDRACT) - Apr 25, 2012
P2, N=36, Ongoing, Sponsor: Grupo Gallego de Investigaci
- | Uplizna (inebilizumab) / Mitsubishi Tanabe, Amgen
New P1 trial: Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Apr 24, 2012
P1, N=28, Recruiting, Sponsor: MedImmune LLC
- |||||||||| Stivarga (regorafenib) / Bayer
New P3 trial, Metastases: CONCUR: Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy (clinicaltrials.gov) - Apr 23, 2012
P3, N=204, Active, not recruiting, Sponsor: Bayer
- Actimmune (interferon gamma-1 b) / Clinigen, Amgen
Trial completion: JakStat2: Topical Interferon Gamma for Macular Edema Secondary to Uveitis (clinicaltrials.gov) - Apr 20, 2012
P1/2, N=5, Completed, Sponsor: National Eye Institute (NEI)
Active, not recruiting --> Completed Recruiting --> Completed
- lopinavir/ritonavir / Generic mfg.
Enrollment change: Drug Interactions Between Lopinavir/Ritonavir and Oral or Patch Contraceptives in HIV Infected Women (clinicaltrials.gov) - Apr 19, 2012
P2, N=32, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed N=54 --> 32
- ONX 0805 / Amgen
Enrollment change: A Single and Multiple-Dose Study of SB1578 (clinicaltrials.gov) - Apr 18, 2012
P1, N=40, Completed, Sponsor: S*BIO
N=54 --> 32 N=64 --> 40
- Vectibix (panitumumab) / Amgen
New P1/2 trial: Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus (clinicaltrials.gov) - Apr 18, 2012
P1/2, N=45, Recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
- | ONX 0805 / Amgen
Trial completion: A Single and Multiple-Dose Study of SB1578 (clinicaltrials.gov) - Apr 18, 2012
P1, N=40, Completed, Sponsor: S*BIO
N=64 --> 40 Active, not recruiting --> Completed
- | Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Trial completion, Metastases: Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Apr 18, 2012
P2, N=26, Completed, Sponsor: Mt. Sinai Medical Center, Miami
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
New P3 trial: PREDICTt: PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease (clinicaltrials.gov) - Apr 17, 2012
P3, N=476, Recruiting, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
- | zoledronic acid / Generic mfg.
Trial completion, Metastases: Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma (clinicaltrials.gov) - Apr 16, 2012
P=N/A, N=24, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Suspended --> Completed
- ||||| Enbrel (etanercept) / Pfizer, Amgen
New P4 trial: Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening (clinicaltrials.gov) - Apr 15, 2012
P4, N=320, Recruiting, Sponsor: Pfizer
- Trial completion: Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas (clinicaltrials.gov) - Apr 13, 2012
P2, N=60, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Completed Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial termination: A Randomized Study of the Site for Growth Factor Injection for Patients Undergoing Autologous Stem Cell Transplantation (clinicaltrials.gov) - Apr 12, 2012
P2, N=35, Terminated, Sponsor: Emory University
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Accrual goal met
- Vectibix (panitumumab) / Amgen
Trial termination: PANORAMIC: Radio-chemotherapy With or Without Panitumumab (Vectibix (clinicaltrials.gov) - Apr 11, 2012
P2, N=4, Terminated, Sponsor: Radboud University
Active, not recruiting --> Terminated; Accrual goal met Recruiting --> Terminated; low recruitment numbers
- Vectibix (panitumumab) / Amgen
Enrollment change: PANORAMIC: Radio-chemotherapy With or Without Panitumumab (Vectibix (clinicaltrials.gov) - Apr 11, 2012
P2, N=4, Terminated, Sponsor: Radboud University
Recruiting --> Terminated; low recruitment numbers N=124 --> 4
- Stivarga (regorafenib) / Bayer
Enrollment closed, Metastases: BAY73-4506 Probe Substrate Study (clinicaltrials.gov) - Apr 11, 2012
P1, N=40, Active, not recruiting, Sponsor: Bayer
N=124 --> 4 Recruiting --> Active, not recruiting
- | Trial completion: High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 11, 2012
P3, N=61, Completed, Sponsor: Roswell Park Cancer Institute
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
New P3 trial: Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids (clinicaltrials.gov) - Apr 10, 2012
P3, N=776, Recruiting, Sponsor: Amgen
- |||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
New P3 trial: FRAME: Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Apr 10, 2012
P3, N=7180, Active, not recruiting, Sponsor: Amgen
- | Parsabiv (etelcalcetide) / Amgen
New P2 trial: Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism (clinicaltrials.gov) - Apr 10, 2012
P2, N=30, Active, not recruiting, Sponsor: KAI Pharmaceuticals
- Enrollment closed, Post-transplantation: Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak) (clinicaltrials.gov) - Apr 10, 2012
P2, N=45, Active, not recruiting, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Campath (alemtuzumab) / Sanofi, Neupogen (filgrastim) / Kyowa Kirin, Amgen, plerixafor / Generic mfg.
Enrollment change: Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim (clinicaltrials.gov) - Apr 9, 2012
P2, N=7, Terminated, Sponsor: University of California, San Francisco
Recruiting --> Active, not recruiting N=20 --> 7
- | Nplate (romiplostim) / Amgen, Kyowa Kirin
Enrollment change: Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Apr 9, 2012
P1/2, N=50, Completed, Sponsor: M.D. Anderson Cancer Center
N=20 --> 7 N=36 --> 50
- | Nplate (romiplostim) / Amgen, Kyowa Kirin
Trial completion: Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Apr 9, 2012
P1/2, N=50, Completed, Sponsor: M.D. Anderson Cancer Center
N=36 --> 50 Active, not recruiting --> Completed
- ||| Uplizna (inebilizumab) / Mitsubishi Tanabe, Amgen, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial initiation date: A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Apr 4, 2012
P2, N=180, Recruiting, Sponsor: MedImmune LLC
Active, not recruiting --> Completed Initiation date: Nov 2011 --> Feb 2012
- | fludarabine IV / Generic mfg., busulfan / Generic mfg.
New P2 trial, Combination therapy: Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning (clinicaltrials.gov) - Apr 4, 2012
P2, N=100, Recruiting, Sponsor: M.D. Anderson Cancer Center
- Enbrel (etanercept) / Pfizer, Amgen
Trial termination: Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients (clinicaltrials.gov) - Apr 3, 2012
P2, N=10, Terminated, Sponsor: Kaysen, George A., M.D., Ph.D.
Initiation date: Nov 2011 --> Feb 2012 Active, not recruiting --> Terminated; We were unable to recruit sufficient patients within the confines of our budget considering the restrains on our recruitment criteria
- |||| Gilotrif (afatinib) / Boehringer Ingelheim
Trial completion: A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 3, 2012
P2, N=94, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Terminated; We were unable to recruit sufficient patients within the confines of our budget considering the restrains on our recruitment criteria Active, not recruiting --> Completed
- |||| Eprex (epoetin alfa) / J&J
Trial completion, HEOR, Cost effectiveness: Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia (clinicaltrials.gov) - Apr 3, 2012
P4, N=492, Completed, Sponsor: Janssen-Cilag B.V.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment closed: Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant (clinicaltrials.gov) - Mar 30, 2012
P2, N=88, Active, not recruiting, Sponsor: Cancer and Leukemia Group B
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Extimia (empegfilgrastim biosimilar) / Biocad
New P2 trial: Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer (clinicaltrials.gov) - Mar 29, 2012
P2, N=60, Completed, Sponsor: Biocad
- | AMG 747 / Amgen
New P2 trial: 20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165) (clinicaltrials.gov) - Mar 29, 2012
P2, N=111, Terminated, Sponsor: Amgen
- | AMG 747 / Amgen
New P2 trial: 20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (clinicaltrials.gov) - Mar 29, 2012
P2, N=121, Terminated, Sponsor: Amgen
- AMG 579 / Amgen
New P1 trial: First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia (clinicaltrials.gov) - Mar 29, 2012
P1, N=50, Terminated, Sponsor: Amgen
- |||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: PRISTINE: Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis (clinicaltrials.gov) - Mar 28, 2012
P4, N=273, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Trial termination, Metastases: Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma (clinicaltrials.gov) - Mar 27, 2012
P2, N=6, Terminated, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed Active, not recruiting --> Terminated
- ||| Enbrel (etanercept) / Pfizer, Amgen
Enrollment change: Evaluation of Etanercept in Patients With Plaque Psoriasis After Stopping Ciclosporin Therapy (clinicaltrials.gov) - Mar 27, 2012
P4, N=120, Completed, Sponsor: Pfizer
Active, not recruiting --> Terminated N=154 --> 120
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Enrollment change, Metastases: Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma (clinicaltrials.gov) - Mar 27, 2012
P2, N=6, Terminated, Sponsor: National Institutes of Health Clinical Center (CC)
N=154 --> 120 N=29 --> 6
- Vectibix (panitumumab) / Amgen
Trial termination: Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma (clinicaltrials.gov) - Mar 26, 2012
P2, N=1, Terminated, Sponsor: Accelerated Community Oncology Research Network
N=29 --> 6 Active, not recruiting --> Terminated; Safety concern in a similar trial enrolling the same patient population
- ||| Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
Trial initiation date: A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Mar 25, 2012
P2, N=170, Recruiting, Sponsor: MedImmune LLC
Active, not recruiting --> Terminated; Safety concern in a similar trial enrolling the same patient population Initiation date: Oct 2011 --> Feb 2012
- Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Trial termination: Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Mar 22, 2012
P=N/A, N=3, Terminated, Sponsor: Comprehensive Cancer Center of Wake Forest University
Initiation date: Oct 2011 --> Feb 2012 Suspended --> Terminated; Slow accrual
- Vectibix (panitumumab) / Amgen
Enrollment change: NITMEC: New Individualized Therapy Trial for Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 22, 2012
P1/2, N=10, Completed, Sponsor: Inova Health Care Services
Suspended --> Terminated; Slow accrual N=50 --> 10
- Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Enrollment change: Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Mar 22, 2012
P=N/A, N=3, Terminated, Sponsor: Comprehensive Cancer Center of Wake Forest University
N=50 --> 10 N=36 --> 3